| Data presented at the 65th Annual Meeting of the American Epilepsy Society -- First presentation of pooled Vimpat® data showed a decrease in partial-onset seizure frequency and consistent efficacy in patients undergoing open-label treatment for up to eight years. -- Long-term treatment with Vimpat® was associated with statistically significant improvements in health-related quality of life standards, including seizure worry, social functioning, and overall health state. ...continued UCBJY |
Monday, December 5, 2011
Long-term Use of Antiepileptic Drug Vimpat( (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment